Literature DB >> 29438057

Complement-Dependent Cytotoxicity Assay.

Thomas D Duensing, Susan R Watson.   

Abstract

A useful feature of therapeutic antibodies is the ability to kill the cells to which they bind. Antibodies are capable of mediating cell killing in a variety of ways. Apoptosis, complement-mediated mechanisms, and antibody-dependent cellular cytotoxicity are all effects that can be assayed to characterize lead antibody candidates. Extensive, multidose characterizations of a series of candidates can be performed in a short amount of time using assays developed for high-throughput flow cytometry systems. Antibodies that contain the Fc portion of the human IgG1 can activate complement-mediated cell death. One way in which they do this is via direct complement killing of tumor cells by the membrane attack complex, a process usually called complement-dependent cytotoxicity.
© 2018 Cold Spring Harbor Laboratory Press.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29438057     DOI: 10.1101/pdb.prot093799

Source DB:  PubMed          Journal:  Cold Spring Harb Protoc        ISSN: 1559-6095


  7 in total

1.  Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism.

Authors:  Akiko Watanabe; Kevin R McCarthy; Masayuki Kuraoka; Aaron G Schmidt; Yu Adachi; Taishi Onodera; Keisuke Tonouchi; Timothy M Caradonna; Goran Bajic; Shengli Song; Charles E McGee; Gregory D Sempowski; Feng Feng; Patricia Urick; Thomas B Kepler; Yoshimasa Takahashi; Stephen C Harrison; Garnett Kelsoe
Journal:  Cell       Date:  2019-05-16       Impact factor: 41.582

2.  Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer.

Authors:  Long Qin; Long Wang; Junchang Zhang; Huinian Zhou; Zhiliang Yang; Yan Wang; Weiwen Cai; Fei Wen; Xiangyan Jiang; Tiansheng Zhang; Huili Ye; Bo Long; Junjie Qin; Wengui Shi; Xiaoying Guan; Zeyuan Yu; Jing Yang; Qi Wang; Zuoyi Jiao
Journal:  Sci Adv       Date:  2022-05-25       Impact factor: 14.957

3.  MHC matching fails to prevent long-term rejection of iPSC-derived neurons in non-human primates.

Authors:  Romina Aron Badin; Aurore Bugi; Susannah Williams; Marta Vadori; Marie Michael; Caroline Jan; Alberto Nassi; Sophie Lecourtois; Antoine Blancher; Emanuele Cozzi; Philippe Hantraye; Anselme L Perrier
Journal:  Nat Commun       Date:  2019-09-25       Impact factor: 14.919

4.  A Strategy to Elicit M2e-Specific Antibodies Using a Recombinant H7N9 Live Attenuated Influenza Vaccine Expressing Multiple M2e Tandem Repeats.

Authors:  Daria Mezhenskaya; Irina Isakova-Sivak; Tatiana Kotomina; Victoria Matyushenko; Min-Chul Kim; Noopur Bhatnagar; Ki-Hye Kim; Sang-Moo Kang; Larisa Rudenko
Journal:  Biomedicines       Date:  2021-02-01

Review 5.  Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection.

Authors:  Bronwyn M Gunn; Shuangyi Bai
Journal:  Hum Vaccin Immunother       Date:  2021-10-06       Impact factor: 3.452

6.  A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety.

Authors:  Nestor Rubio-Infante; Yoel Adbel Ramírez-Flores; Elena Cristina Castillo; Omar Lozano; Gerardo García-Rivas; Guillermo Torre-Amione
Journal:  Front Cell Dev Biol       Date:  2022-03-30

7.  Purification of T Cell Populations.

Authors:  Ivan J Fuss
Journal:  Curr Protoc Immunol       Date:  2020-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.